Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients—author's reply

LINKED CONTENT This article is linked to Papatheodoridis et al papers. To view these articles, visit https://doi.org/10.1111/apt.17093 and https://doi.org/10.1111/apt.17117

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2022-09, Vol.56 (5), p.918-919
Main Author: Papatheodoridis, George V.
Format: Article
Language:English
Subjects:
Bone mineral density
Hepatitis B
Renal function
Tenofovir
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2556-fa28a5fdcf6796f7b9daf1672ad6d5a972243e1ca4994b1391bcd0e8b5ef5b303
container_end_page 919
container_issue 5
container_start_page 918
container_title Alimentary pharmacology & therapeutics
container_volume 56
creator Papatheodoridis, George V.
description LINKED CONTENT This article is linked to Papatheodoridis et al papers. To view these articles, visit https://doi.org/10.1111/apt.17093 and https://doi.org/10.1111/apt.17117
doi_str_mv 10.1111/apt.17146
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2699956531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2699565825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2556-fa28a5fdcf6796f7b9daf1672ad6d5a972243e1ca4994b1391bcd0e8b5ef5b303</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhS0EEpeWBW9giQV0kdZ2rp0bdqUqP1IlWJR1NLHHjavEDrZDe3c8BE_D4_Ak-BIWFRLejCV_M2d8DiEvODvl5ZzBnE95w7fqEdnwWslKsFo9JhsmVFuJHa-fkmcp3TLGVMPEhvy8NC6H6GB8Q_UA_gYTdZ5G9DBSu3idXfAUvKF98Egn5zGWF4M-ubynYDNGmu5c1oPzN9TGMNGMPtjwzUVqXApzDPfuMGuCCBlpDg8AGMEWqckZPMjqIQbvNB1whuyyS_QtPdzQ5_Tr-w9Y8hDiq1TWm8f9MXliYUz4_G89Il_eXV5ffKiuPr3_eHF-VWkhpaosiB1Ia7RVTats07cGLFeNAKOMhLYRYlsj17Bt223P65b32jDc9RKt7GtWH5HX69zyk68LptxNLmkcR_AYltQVZ9tWKlnzgr78B70NSyxWrlSBdkIW6mSldAwpRbTdHF1xZ99x1h1S7EqK3Z8UC3u2snduxP3_we788_Xa8RvzJ6TJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2699565825</pqid></control><display><type>article</type><title>Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients—author's reply</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Papatheodoridis, George V.</creator><creatorcontrib>Papatheodoridis, George V.</creatorcontrib><description>LINKED CONTENT This article is linked to Papatheodoridis et al papers. To view these articles, visit https://doi.org/10.1111/apt.17093 and https://doi.org/10.1111/apt.17117</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.17146</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Bone mineral density ; Hepatitis B ; Renal function ; Tenofovir</subject><ispartof>Alimentary pharmacology &amp; therapeutics, 2022-09, Vol.56 (5), p.918-919</ispartof><rights>2022 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2022 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2556-fa28a5fdcf6796f7b9daf1672ad6d5a972243e1ca4994b1391bcd0e8b5ef5b303</cites><orcidid>0000-0002-3518-4060</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Papatheodoridis, George V.</creatorcontrib><title>Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients—author's reply</title><title>Alimentary pharmacology &amp; therapeutics</title><description>LINKED CONTENT This article is linked to Papatheodoridis et al papers. To view these articles, visit https://doi.org/10.1111/apt.17093 and https://doi.org/10.1111/apt.17117</description><subject>Bone mineral density</subject><subject>Hepatitis B</subject><subject>Renal function</subject><subject>Tenofovir</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1TAQhS0EEpeWBW9giQV0kdZ2rp0bdqUqP1IlWJR1NLHHjavEDrZDe3c8BE_D4_Ak-BIWFRLejCV_M2d8DiEvODvl5ZzBnE95w7fqEdnwWslKsFo9JhsmVFuJHa-fkmcp3TLGVMPEhvy8NC6H6GB8Q_UA_gYTdZ5G9DBSu3idXfAUvKF98Egn5zGWF4M-ubynYDNGmu5c1oPzN9TGMNGMPtjwzUVqXApzDPfuMGuCCBlpDg8AGMEWqckZPMjqIQbvNB1whuyyS_QtPdzQ5_Tr-w9Y8hDiq1TWm8f9MXliYUz4_G89Il_eXV5ffKiuPr3_eHF-VWkhpaosiB1Ia7RVTats07cGLFeNAKOMhLYRYlsj17Bt223P65b32jDc9RKt7GtWH5HX69zyk68LptxNLmkcR_AYltQVZ9tWKlnzgr78B70NSyxWrlSBdkIW6mSldAwpRbTdHF1xZ99x1h1S7EqK3Z8UC3u2snduxP3_we788_Xa8RvzJ6TJ</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Papatheodoridis, George V.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3518-4060</orcidid></search><sort><creationdate>202209</creationdate><title>Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients—author's reply</title><author>Papatheodoridis, George V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2556-fa28a5fdcf6796f7b9daf1672ad6d5a972243e1ca4994b1391bcd0e8b5ef5b303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bone mineral density</topic><topic>Hepatitis B</topic><topic>Renal function</topic><topic>Tenofovir</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papatheodoridis, George V.</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papatheodoridis, George V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients—author's reply</atitle><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle><date>2022-09</date><risdate>2022</risdate><volume>56</volume><issue>5</issue><spage>918</spage><epage>919</epage><pages>918-919</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>LINKED CONTENT This article is linked to Papatheodoridis et al papers. To view these articles, visit https://doi.org/10.1111/apt.17093 and https://doi.org/10.1111/apt.17117</abstract><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/apt.17146</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-3518-4060</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-2813
ispartof Alimentary pharmacology & therapeutics, 2022-09, Vol.56 (5), p.918-919
issn 0269-2813
1365-2036
language eng
recordid cdi_proquest_miscellaneous_2699956531
source Wiley-Blackwell Read & Publish Collection
subjects Bone mineral density
Hepatitis B
Renal function
Tenofovir
title Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients—author's reply
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A43%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Editorial:%20changes%20in%20renal%20function%20and%20bone%20mineral%20density%20after%20switching%20from%20tenofovir%20disoproxil%20fumarate%20to%20tenofovir%20alafenamide%20in%20chronic%20hepatitis%20B%20patients%E2%80%94author's%20reply&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Papatheodoridis,%20George%20V.&rft.date=2022-09&rft.volume=56&rft.issue=5&rft.spage=918&rft.epage=919&rft.pages=918-919&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.17146&rft_dat=%3Cproquest_cross%3E2699565825%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2556-fa28a5fdcf6796f7b9daf1672ad6d5a972243e1ca4994b1391bcd0e8b5ef5b303%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2699565825&rft_id=info:pmid/&rfr_iscdi=true